GHRHR: Growth hormone-releasing hormone receptor
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Receptor for GRF, coupled to G proteins which activate adenylyl cyclase.
- Drugs that act on it: 2
- Approved: 2
- In phases 1 to 3: 0
- Sponsors: 2
Who Is On It, and How Far Along
Every drug ChEMBL records acting on GHRHR, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Protein or peptide
The Landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.| Tesamorelin | Approved | Theratechnologies | Protein or peptide | Agonist | Growth hormone-releasing hormone receptor agonist | 3 | — |
| Sermorelin acetate | Approved | Merck KGaA | Protein or peptide | Agonist | Growth hormone-releasing hormone receptor agonist | 0 | — |
Open Trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 3 in all, from ClinicalTrials.gov.| Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease | Tesamorelin | Phase 2 | Recruiting | Hudson Biotech | 2026-03-19 |
| Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV | Tesamorelin | Phase 2 | Recruiting | Massachusetts General Hospital | 2024-08-15 |
| Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury | Tesamorelin | Phase 2 | Recruiting | Johns Hopkins University | 2017-05-12 |
Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Isolated growth hormone deficiency, type 4
- 0.69
- Isolated growth hormone deficiency type IB
- 0.47
- Hypopituitarism
- 0.43
- HIV-Associated Lipodystrophy Syndrome
- 0.37
- Neurodegenerative disease
- 0.33
- Adolescent idiopathic scoliosis
- 0.28
- Abdominal obesity
- 0.26
- Ileostomy
- 0.20
- Hereditary disease
- 0.19
- Gastric ulcer
- 0.19
- Hemorrhage
- 0.19
- Radius fracture
- 0.11
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2032, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q02643, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets